抗精神病药物在物质所致精神病后预防复发的真实世界效果
该研究基于瑞典登记数据,纳入1772例首次临床诊断为大麻所致精神病(CIP)的患者,采用个体内Cox回归比较使用不同口服或长效针剂(LAI)抗精神病药与未使用期间的精神病住院风险。结果显示,任何抗精神病药使用与精神病住院风险降低相关(aHR 0.75;95%CI 0.67-0.84),其中LAI、氯氮平和口服阿立哌唑关联更明显。
要点
- CIP后使用任何抗精神病药与精神病住院风险降低相关,aHR 0.75(95%CI 0.67-0.84)。
- 阿立哌唑LAI(aHR 0.27)和奥氮平LAI(aHR 0.28)关联的风险降低幅度较大。
- 氯氮平(aHR 0.55)和口服阿立哌唑(aHR 0.64)也与风险降低相关。
核心结论
- 首次临床诊断CIP后,使用抗精神病药与精神病住院风险降低相关,尤其是LAI、氯氮平和口服阿立哌唑。
研究设计与样本
- 基于瑞典国家患者登记和微观数据分析社会保险登记,识别1772例(84.1%男性)新发CIP患者。
- 采用PRE2DUP方法从处方药登记构建用药时段,使用个体内Cox回归比较用药与未用药期间结局风险。
主要发现
- 首次诊断平均年龄26.6岁(s.d.=8.3),1343例(75.8%)使用过抗精神病药,914例(51.3%)随访期间因精神病住院。
- 任何抗精神病药使用与精神病住院风险降低相关(aHR 0.75;95%CI 0.67-0.84)。
- 阿立哌唑LAI(aHR 0.27;95%CI 0.14-0.51)和奥氮平LAI(aHR 0.28;95%CI 0.15-0.53)与风险降低相关。
- 氯氮平(aHR 0.55;95%CI 0.34-0.90)、口服阿立哌唑(aHR 0.64;95%CI 0.45-0.91)、抗精神病药多药联用(aHR 0.74;95%CI 0.63-0.87)和口服奥氮平(aHR 0.81;95%CI 0.69-0.94)与风险降低相关。
关键数值与推荐
- 主要结局为因任何精神病发作导致的住院。
- 使用个体内Cox回归模型比较不同口服或LAI抗精神病药使用期与未使用期的结局风险。
临床怎么用
- CIP后处方抗精神病药时应考虑其预防精神病复发的潜在获益。
- 处方者可考虑更多使用LAI以改善CIP后的治疗结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cannabis use is linked to treatment non-adherence and relapses in psychotic disorders. Antipsychotic medication is effective for relapse prevention in primary psychoses, but its effectiveness after cannabis-induced psychosis (CIP) remains unclear. AIMS: To examine the effectiveness of antipsychotic medication for relapse prevention following the first clinically diagnosed CIP. METHOD: A cohort of 1772 patients (84.1% men) with incident CIP was identified from the Swedish National Patient and Micro Data for Analyses of Social Insurance registers. The primary outcome was hospitalisation due to any psychotic episode. Drug use data were collected from the Prescribed Drug Register and modelled into drug use periods using the PRE2DUP method. A within-individual Cox regression model was used to study the risk of outcomes during the use of different oral or long-acting injectable (LAI) antipsychotics compared with non-use. RESULTS: The mean age at first diagnosis was 26.6 years (s.d. = 8.3). Of the cohort, 1343 (75.8%) used antipsychotics and 914 (51.3%) experienced psychosis hospitalisation during the follow-up. Any antipsychotic use was associated with a decreased risk of psychosis hospitalisation (adjusted hazard ratio (aHR) 0.75; 95% CI 0.67-0.84). Specific antipsychotics associated with decreased risk included aripiprazole LAI (aHR 0.27; 95% CI 0.14-0.51), olanzapine LAI (aHR 0.28; 95% CI 0.15-0.53), clozapine (aHR 0.55; 95% CI 0.34-0.90), oral aripiprazole (aHR 0.64; 95% CI 0.45-0.91), antipsychotic polytherapy (aHR 0.74; 95% CI 0.63-0.87) and oral olanzapine (aHR 0.81; 95% CI 0.69-0.94). CONCLUSIONS: In particular, LAIs, clozapine and oral aripiprazole were associated with a decreased risk of psychosis relapse following CIP. Prescribers should consider using more LAIs for better treatment outcomes after CIP.
引用
- Mustonen A, Taipale H, Denissoff A, et al. Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis. Br J Psychiatry. 2025. PMID: 40326094. doi:10.1192/bjp.2025.72
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。